ADMS - Adamas Pharmaceuticals, Inc.
| Previous Close | 11.52 |
| Open | 11.63 |
| Bid | 10.81 x 1000 |
| Ask | 10.84 x 200 |
| Day's Range | 10.60 - 11.94 |
| 52 Week Range | 10.58 - 44.00 |
| Volume | 369,012 |
| Avg. Volume | 619,889 |
| Market Cap | 296.317M |
| Beta (3Y Monthly) | 2.65 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.10 |
| Earnings Date | Nov 1, 2017 - Nov 6, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 41.60 |
- GlobeNewswire•5 days ago
Adamas to Present at Three November Investor Conferences
EMERYVILLE, Calif., Nov. 09, 2018 -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central.
- GlobeNewswire•6 days ago
Factors of Influence in 2018, Key Indicators and Opportunity within Apptio, Adamas Pharmaceuticals, NEXEO SOLUTIONS, Computer Programs and, Solaris Oilfield Infrastructure, and SPX — New Research Emphasizes Economic Growth
NEW YORK, Nov. 08, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Thomson Reuters StreetEvents•12 days ago
Edited Transcript of ADMS earnings conference call or presentation 1-Nov-18 8:30pm GMT
Q3 2018 Adamas Pharmaceuticals Inc Earnings Call
- Motley Fool•12 days ago
The Probable Reason Why Adamas Pharmaceuticals Inc. Is Down Big Today
Shares fall hard after the company reports good news. What's going on?
- Associated Press•13 days ago
Adamas: 3Q Earnings Snapshot
The Emeryville, California-based company said it had a loss of $1.22 per share. The results beat Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was ...
- GlobeNewswire•13 days ago
Adamas Reports Third Quarter 2018 Financial Results
GOCOVRI™ (amantadine) extended release capsules sales increased to $10.6 million for the third quarter, with ~4,740 fulfilled prescriptions EMERYVILLE, Calif., Nov. 01, 2018.
- Benzinga•13 days ago
The Daily Biotech Pulse: AbbVie's Leukemia Drug Trial Meets Endpoint, Denali Strikes Collaboration Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 1) Merck & Co., Inc. (NYSE: MRK )(announced FDA approval ...
- GlobeNewswire•19 days ago
Adamas to Announce Third Quarter 2018 Financial Results and Host Conference Call on November 1, 2018
Adamas Pharmaceuticals, Inc. (ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system disorders, today announced that it will report third quarter 2018 financial results on Thursday, November 1, 2018, after market close. Subsequently, Adamas’ management team will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the financial results and provide a corporate update. The conference call can be accessed by dialing 844-215-3280 for participants in the U.S. or Canada and 484-747-6383 for international callers.
- Reuters•21 days ago
China cutting rare earth output, unnerving global manufacturers
LONDON/HOUSTON Oct 24 (Reuters) - The Chinese government is limiting domestic production of rare earth minerals in the second half of the year, a move likely to crimp international exports and send prices for the critical materials soaring, according to data from Adamas Intelligence. China is by far the world's largest producer and consumer of rare earths, a group of 17 elements used to make electric vehicles and consumer electronics. The move is already forcing manufacturers to scour the globe for alternative supplies.
- GlobeNewswire•29 days ago
Consolidated Research: 2018 Summary Expectations for Freightcar America, Star Bulk Carriers, Avis Budget Group, Adamas Pharmaceuticals, Model N, and Amphastar Pharmaceuticals — Fundamental Analysis, Key Performance Indications
NEW YORK, Oct. 16, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Motley Fool•last month
Why Adamas Pharmaceuticals, Inc. Stock Sank in September
Adamas' steady march lower continued in September. Here's why.
- GlobeNewswire•last month
Adamas Presents Final Results from the Two-Year, Phase 3 Open-Label Study of GOCOVRI™ in Parkinson’s Disease Patients with Dyskinesia
Adamas Pharmaceuticals, Inc. (ADMS), a fully integrated pharmaceutical company pioneering time-dependent medicines for central nervous system (CNS) disorders, today announced the presentation of final results from EASE LID 2, the company’s two-year Phase 3 open-label study of GOCOVRI™ (amantadine) extended release capsules, the first and only medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.
- GlobeNewswire•last month
Adamas Announces New Employment Inducement Grant
Adamas Pharmaceuticals, Inc. (ADMS) today announced that the compensation committee of the company’s board of directors granted nine new employees the option to purchase an aggregate of 49,210 shares of the company’s common stock, at a per share exercise price of $17.83, the closing trading price on October 5, 2018, and restricted stock units to acquire 8,198 shares of the company’s common stock. The stock options and restricted stock units vest over four years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company.
- Simply Wall St.•last month
When Can We Expect A Profit From Adamas Pharmaceuticals Inc (NASDAQ:ADMS)?
Adamas Pharmaceuticals Inc’s (NASDAQ:ADMS): Adamas Pharmaceuticals, Inc. discovers, develops, and sells therapies for chronic neurologic disorders. The US$543m market-cap posted a loss in its most recent financial year of -US$89m Read More...
- GlobeNewswire•last month
Adamas Announces Publication of Data Demonstrating Dyskinesia’s Impact on Activities of Daily Living in People with Parkinson’s Disease
Adamas Pharmaceuticals, Inc. (ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system (CNS) disorders, today announced that pooled Phase 3 data of GOCOVRI™ (amantadine) extended release capsules were published online in Parkinsonism and Related Disorders1. The paper entitled, Impact of dyskinesia on activities of daily living in Parkinson's disease: Results from pooled Phase 3 ADS-5102 clinical trials, concluded that dyskinesias in people with Parkinson’s disease can impact a patient's activities of daily living (ADLs) across multiple tasks, and that treatment with GOCOVRI can help ameliorate the impairment. GOCOVRI is the first and only medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.
Market Realist•2 months agoA Financial Overview of Supernus Pharmaceuticals in September
In the second quarter, Supernus Pharmaceuticals (SUPN) reported net revenues of $99.5 million compared to $75.8 million in the second quarter of 2017. In the first half, Supernus Pharmaceuticals generated net revenues of $190.0 million compared to $133.4 million in the first half of 2017.
Market Realist•2 months agoSupernus Pharmaceuticals Garners 89% ‘Buy’ Ratings in September
On September 11, Supernus Pharmaceuticals (SUPN) stock closed at $48.80, up 1.99% from its closing price of $47.85 on September 10. The company’s September 11 stock price was 26.0% below its 52-week high of $61.25 on June 29. Supernus Pharmaceuticals hit its 52-week low of $33.30 on November 7, 2017.
- GlobeNewswire•2 months ago
Adamas Announces New Employment Inducement Grant
Adamas Pharmaceuticals, Inc. (ADMS) today announced that the compensation committee of the company’s board of directors granted six new employees the option to purchase an aggregate of 68,251 shares of the company’s common stock, at a per share exercise price of $22.76, the closing trading price on September 10, 2018, and restricted stock units to acquire 11,373 shares of the company’s common stock. The stock options and restricted stock units vest over four years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company.
- GlobeNewswire•3 months ago
Investor Expectations to Drive Momentum within Mazor Robotics, Kinross Gold, Mimecast, DBV Technologies S.A., Adamas Pharmaceuticals, and Adverum Biotechnologies — Discovering Underlying Factors of Influence
NEW YORK, Aug. 20, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Mazor ...
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of ADMS earnings conference call or presentation 2-Aug-18 8:30pm GMT
Q2 2018 Adamas Pharmaceuticals Inc Earnings Call
- Benzinga•3 months ago
The Daily Biotech Pulse: Zafgen Executive Departs; Adamas, Acceleron Accelerate On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 2) Akcea Therapeutics Inc (NASDAQ: AKCA ) Arbutus Biopharma Corp ...
- Zacks•3 months ago
Adamas Pharmaceuticals (ADMS) Reports Q2 Loss, Tops Revenue Estimates
Adamas (ADMS) delivered earnings and revenue surprises of 10.64% and 56.17%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•3 months ago
Adamas: 2Q Earnings Snapshot
On a per-share basis, the Emeryville, California-based company said it had a loss of $1.26. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
